Repotrectinib

5 trials 5 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

5 Recruiting

0 Completed trials

6 Sponsors

12 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 1 Phase II: 2 Phase I/II: 1 Phase I (FiH): 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 1 Non-small cell lung cancer stage IIIB 1

Sponsors using this IMP

Turning Point Therapeutics Inc. 2 Bristol-Myers Squibb Services Unlimited Company 1 Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer 1 Groupe Français de Pneumo-Oncologie 1 Medica Scientia Innovation Research S.L. 1 Medical University Of Vienna 1

All trials

5 total

A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting

2023-505604-32-00 Phase III 10 countries Bristol-Myers Squibb Services Unlimited Company
Phase 1/2 Open Label solid tumour Safety and Tolerability study in Pediatric and Young Adult subjects. Recruiting

2023-506464-14-00 Phase I/II 4 countries Turning Point Therapeutics Inc.
A phase II study assessing safety and efficacy of REPotrectinib in ROS1-positive non-small cell lung cancer patients with active brain mEtas… Recruiting

2023-508112-35-00 Phase II 3 countries Medica Scientia Innovation Research S.L.; Medical University Of Vienna
OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting

2023-509073-23-00 Phase II 1 country Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer; Groupe Français de P…
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-00… Recruiting

2024-512606-25-00 Phase I (FiH) 9 countries Turning Point Therapeutics Inc.

Showing 1–5 of 5 trials

← All drugs A–Z